MTNB · Insider Trading
Matinas BioPharma Holdings, Inc.
Every open-market purchase and sale reported by MTNB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-13 | Adam K Stern | 10%+ Owner | X | +1,067,145 | +$400.63K |
| 2026-08-13 | Sanitam Partners LLC | 10%+ Owner | J | −4,800,042 deriv. | — |
| 2025-05-02 | An Evelyn D | Director | A | +11,600 deriv. | — |
| 2025-05-02 | Edward Neugeboren | Director | A | +11,600 deriv. | — |
| 2025-05-02 | Jerome D Jabbour | President and CEO | A | +70,100 deriv. | — |
| 2025-05-02 | Robin L Smith | Director | A | +11,600 deriv. | — |
| 2025-05-02 | Keith Murphy | Director | A | +11,600 deriv. | — |
| 2025-04-10 | Sanitam Partners LLC | 10%+ Owner | Buy | +2,400,021 deriv. | — |
| 2025-04-10 | Robert J Eide | 10%+ Owner | Buy | — | — |
| 2025-04-10 | Pembroke & Partners LLC | 10%+ Owner | Buy | +1,679,674 deriv. | — |
| 2023-12-15 | Hui Liu | Chief Technology Officer | A | +1,000,000 deriv. | — |
| 2023-12-15 | Keith A Kucinski | Chief Financial Officer | A | +1,000,000 deriv. | — |
| 2023-12-15 | James J. Ferguson III | Chief Medical Officer | A | +1,200,000 deriv. | — |
| 2023-12-15 | Jerome D Jabbour | President and CEO | A | +3,500,000 deriv. | — |
| 2023-12-15 | Theresa Matkovits | Chief Development Officer | A | +1,300,000 deriv. | — |
| 2023-12-15 | Thomas Hoover | Chief Business Officer | A | +1,000,000 deriv. | — |
| 2023-11-03 | Eric J Ende | Director | A | +437,244 deriv. | — |
| 2023-11-03 | Natasha Giordano | Director | A | +437,244 deriv. | — |
| 2023-11-03 | Matthew Wikler | Director | A | +437,244 deriv. | — |
| 2023-11-03 | Herbert J Conrad | Director | A | +437,244 deriv. | — |
| 2023-11-03 | Kathryn Penkus Corzo | Director | A | +437,244 deriv. | — |
| 2023-11-03 | James S Scibetta | Director | A | +437,244 deriv. | — |
| 2022-12-22 | Jerome D Jabbour | President and CEO | A | +1,988,300 deriv. | — |
| 2022-12-22 | Thomas Hoover | Chief Business Officer | A | +475,000 deriv. | — |
| 2022-12-22 | Hui Liu | Chief Technology Officer | A | +625,000 deriv. | — |
| 2022-12-22 | Keith A Kucinski | Chief Financial Officer | A | +625,000 deriv. | — |
| 2022-12-22 | James J. Ferguson III | Chief Medical Officer | A | +625,000 deriv. | — |
| 2022-12-22 | Theresa Matkovits | Chief Development Officer | A | +625,000 deriv. | — |
| 2022-11-16 | Eric J Ende | Director | A | +142,657 deriv. | — |
| 2022-11-16 | Natasha Giordano | Director | A | +142,657 deriv. | — |
| 2022-11-16 | Kathryn Penkus Corzo | Director | A | +142,657 deriv. | — |
| 2022-11-16 | James S Scibetta | Director | A | +142,657 deriv. | — |
| 2022-11-16 | Matthew Wikler | Director | A | +142,657 deriv. | — |
| 2022-11-16 | Herbert J Conrad | Director | A | +142,657 deriv. | — |
| 2022-07-05 | Herbert J Conrad | Director | G | — | — |
| 2022-01-03 | Matthew Wikler | Director | A | +7,859 | — |
| 2021-12-15 | Theresa Matkovits | Chief Development Officer | A | +500,000 deriv. | — |
| 2021-12-15 | Keith A Kucinski | Chief Financial Officer | A | +500,000 deriv. | — |
| 2021-12-15 | Raphael J Mannino | Chief Scientific Officer | A | +275,000 deriv. | — |
| 2021-12-15 | Liu Hui | Chief Technology Officer | A | +275,000 deriv. | — |
| 2021-12-15 | Jerome D Jabbour | President and CEO | A | +1,658,100 deriv. | — |
| 2021-12-15 | Thomas Hoover | Chief Business Officer | A | +850,000 deriv. | — |
| 2021-12-15 | James J. Ferguson III | Chief Medical Officer | A | +587,600 deriv. | — |
| 2021-11-02 | Herbert J Conrad | Director | A | +90,882 deriv. | — |
| 2021-11-02 | Matthew Wikler | Director | A | +90,882 deriv. | — |
| 2021-11-02 | Kathryn Penkus Corzo | Director | A | +181,763 deriv. | — |
| 2021-11-02 | Natasha Giordano | Director | A | +90,882 deriv. | — |
| 2021-11-02 | James S Scibetta | Director | A | +90,882 deriv. | — |
| 2021-11-02 | Eric J Ende | Director | A | +90,882 deriv. | — |
| 2021-10-01 | Matthew Wikler | Director | A | +6,106 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Adam K Stern | Director | 2,284 | $3.79K |
| Jerome D Jabbour | President and CEO | 1,120 | $1.86K |
| Robert J Eide | 10%+ Owner | 100 | $166 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MTNB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.